RE:RE:A new prospectusEoganacht ... I was in the prospectus in SEDAR.
That's gonna be to finance the NMIBC Ph. 2b and advance the R&D in the other indications.
Strange that nobody raised this new indication mentioned in today's press release:
Our primary focus is and remains the successful completion of this pivotal Phase II study; however, the Company, through Arkady Mandel, MD, PhD, DSc, Chief Scientific Officer of Theralase continues to research and develop our PDCs for the treatment of other oncological indications, such as Glioblastoma Multiforme ("GBM") , Non-Small Cell Lung Cancer ("NSCLC") and most recently non-melanoma related skin cancer."